147 related articles for article (PubMed ID: 15004434)
1. Role of Angiotensin-converting enzyme and neutral endopeptidase in flow-dependent remodeling.
Korshunov VA; Massett MP; Carey RM; Berk BC
J Vasc Res; 2004; 41(2):148-56. PubMed ID: 15004434
[TBL] [Abstract][Full Text] [Related]
2. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
Pu Q; Larouche I; Schiffrin EL
Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
[TBL] [Abstract][Full Text] [Related]
3. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.
Cao Z; Burrell LM; Tikkanen I; Bonnet F; Cooper ME; Gilbert RE
Kidney Int; 2001 Aug; 60(2):715-21. PubMed ID: 11473654
[TBL] [Abstract][Full Text] [Related]
4. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
Pu Q; Touyz RM; Schiffrin EL
J Hypertens; 2002 May; 20(5):899-907. PubMed ID: 12011651
[TBL] [Abstract][Full Text] [Related]
5. Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake.
Azizi M; Lamarre-Cliche M; Labatide-Alanore A; Bissery A; Guyene TT; Ménard J
J Am Soc Nephrol; 2002 Oct; 13(10):2454-63. PubMed ID: 12239234
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
Raasch W; Dominiak P; Dendorfer A
J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
[TBL] [Abstract][Full Text] [Related]
7. The cardiovascular actions of omapatrilat in spontaneously hypertensive rats.
Dong Y; Zhou H; Shaffer E; Atamas N; Liao WC; Wei C
Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S1-5. PubMed ID: 11716799
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo.
Bäcklund T; Palojoki E; Grönholm T; Eriksson A; Vuolteenaho O; Laine M; Tikkanen I
Pharmacol Res; 2001 Nov; 44(5):411-8. PubMed ID: 11712872
[TBL] [Abstract][Full Text] [Related]
9. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
[TBL] [Abstract][Full Text] [Related]
10. Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats.
Pu Q; Schiffrin EL
Am J Hypertens; 2001 Oct; 14(10):1067-72. PubMed ID: 11710787
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
[TBL] [Abstract][Full Text] [Related]
12. Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.
Mifsud SA; Burrell LM; Kubota E; Jaworski K; Cooper ME; Wilkinson-Berka JL
Clin Exp Hypertens; 2004 Jan; 26(1):69-80. PubMed ID: 15000298
[TBL] [Abstract][Full Text] [Related]
13. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
Jandeleit-Dahm K; Lassila M; Davis BJ; Candido R; Johnston CI; Allen TJ; Burrell LM; Cooper ME
J Hypertens; 2005 Nov; 23(11):2071-82. PubMed ID: 16208151
[TBL] [Abstract][Full Text] [Related]
14. Vasopeptidase inhibition: a new concept in blood pressure management.
Burnett JC
J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
[TBL] [Abstract][Full Text] [Related]
15. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats.
Intengan HD; Schiffrin EL
Hypertension; 2000 Jun; 35(6):1221-5. PubMed ID: 10856267
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor.
Azizi M; Massien C; Michaud A; Corvol P
Hypertension; 2000 Jun; 35(6):1226-31. PubMed ID: 10856268
[TBL] [Abstract][Full Text] [Related]
17. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.
Kubota E; Dean RG; Hubner RA; Casley DJ; Johnston CI; Burrell LM
Clin Sci (Lond); 2003 Sep; 105(3):339-45. PubMed ID: 12741953
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
[TBL] [Abstract][Full Text] [Related]
19. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats.
Pu Q; Amiri F; Gannon P; Schiffrin EL
J Hypertens; 2005 Feb; 23(2):401-9. PubMed ID: 15662229
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
